Brief: Corbus Pharmaceuticals' cash runway expected through third-quarter 2027
11/03/2025 13:33
March 11 (Reuters) - Corbus Pharmaceuticals Holdings Inc CRBP.O: CORBUS PHARMACEUTICALS Q4 NET INCOME USD -9.53 MILLION CORBUS PHARMACEUTICALS Q4 BASIC EPS USD -0.78 CORBUS PHARMACEUTICALS Q4 OPERATING EXPENSES USD 12.605 MILLION CORBUS - CASH RUNWAY EXPECTED THROUGH Q3 2027 Source text: nGNX6xPKY8 Further company coverage: CRBP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corbus Pharmaceuticals Holdings
See all newsU.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-AI stocks, energy companies, Johnson & Johnson
U.S. STOCKS ON THE MOVE-US energy stocks, Baldwin, Johnson & Johnson
Corbus gains on weight-loss data for obesity drug in early-stage study